ClinicalTrials.gg
Active, not recruitingNCT05878769Updated Nov 13, 2026

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Astegolimab in Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 480 sites in 40 countries. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Now Active, not recruitingNow Recruiting+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.

Started
2023
with 1 other
Phase 3
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is one of 2 that started in 2023, is one of 2 in phase 3, and was the 7th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • chronic obstructive pulmonary disease, COPD
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the 52-week treatment period in an astegolimab parent study

Exclusion criteria

Exclusion Criteria:

  • Withdrawal of consent and/or premature discontinuation from parent study
  • Any permanent discontinuation of study drug in parent study
  • Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment
  • Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study
  • Any new pulmonary disease other than (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study
  • Any new unstable cardiac disease, myocardial infarction, or Class III or IV heart failure since enrolling in the parent study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Open-Label Extension

    Eligible participants from parent studies GB43311 and GB44332 will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) until the end of the study

    Drug: Astegolimab

Interventions

  • Participants will receive SC astegolimab Q2W

06

What researchers measure

Primary outcomes

  1. Incidence of all adverse events (AEs)

    Time frame: Up to 12 weeks after last dose of study treatment

07

Study locations

480 sites

Showing the first 100 of 480 sites across 40 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 48 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 26, 2023
StartActual
Jun 28, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting→Active, not recruiting
changed Nov 12, 2026 · changed Nov 13, 2026
Sites
10 sites added, 11 sites removed. 476 sites changed recruiting status (444 now recruiting, 18 now completed, …)
Show 476 sites
  • UAB Lung Health Center · Birmingham, United Statesno status→Recruiting
  • SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS · Dothan, United Statesno status→Recruiting
  • Jasper Summit Research LLC · Jasper, United Statesno status→Recruiting
  • Pulmonary Associates of Mobile PC · Mobile, United Statesno status→Recruiting
  • Pulmonary Associates Deer Valley Office · Phoenix, United Statesno status→Recruiting
  • AES - DRS - Synexus Clinical Research US, Inc. - Tucson · Tucson, United Statesno status→Recruiting
  • Kern Allergy and Medical Research · Bakersfield, United Statesno status→Recruiting
  • Cadena Care Institute, LLC · Poway, United Statesno status→Recruiting
  • Apex Clinical Research · San Diego, United Statesno status→Completed
  • St Francis Medical Institute ClinEdge PPDS · Clearwater, United Statesno status→Recruiting
  • Finlay Medical Research Corporation · Greenacres City, United Statesno status→Recruiting
  • Flourish Research - Leesburg - PPDS · Leesburg, United Statesno status→Recruiting
  • Advanced Pulmonary Research Institute · Loxahatchee Groves, United Statesno status→Recruiting
  • San Marcus Research Clinic Inc. · Miami, United Statesno status→Recruiting
  • Finlay Medical Research Corporation · Miami, United Statesno status→Recruiting
  • Oceane7 Medical & Research Center, Inc. · Miami, United Statesno status→Recruiting
  • Research Institute of South Florida Inc · Miami, United Statesno status→Recruiting
  • Diverse Clinical Research, LLC · Miami, United Statesno status→Recruiting
  • Central Florida Pulmonary Group, PA · Orlando, United Statesno status→Recruiting
  • Florida Institute for Clinical Research, LLC · Orlando, United Statesno status→Recruiting
  • Flourish Research - Orlando - PPDS · Winter Park, United Statesno status→Recruiting
  • Pivotal Research Solutions · Stonecrest, United Statesno status→Recruiting
  • Northwestern Center for Clinical Research · Chicago, United Statesno status→Recruiting
  • ASHA Clinical Research - ClinEdge - PPDS · Hammond, United Statesno status→Recruiting
  • Best Clinical Trials · New Orleans, United Statesno status→Recruiting
  • Paul A. Shapero, MD, PA · Bangor, United Statesno status→Recruiting
  • Exordia Medical Research, Inc. · Fall River, United Statesno status→Recruiting
  • Pulmonary Research Institute of Southeast Michigan · Farmington Hills, United Statesno status→Recruiting
  • Flushing Road Internal Medicine and Pediatrics - F · Flint, United Statesno status→Recruiting
  • Revive Research Institute · Southfield, United Statesno status→Recruiting
  • …and 446 more on the registry record
Show 10 added (2 China, 2 Poland, 1 United States, 1 Argentina, 1 Germany, 1 South Africa, 1 Spain, 1 Sweden)
  • ClinSearch, LLC - M3 WR - 6035 Shallowford Rd · Chattanooga, United States
  • CEDIR - Centro de Diagnóstico Y Rehabilitación · Santa Fe, Argentina
  • The First Hospital of Changsha · Changsha, China
  • The Third Hospital of Changsha · Changsha, China
  • AES - DRS - Synexus Berlin Research Centre · Berlin, Germany
  • Centrum Alergologii sp. z.o.o. · Poznan, Poland
  • Centrum Medyczne Lukamed sp. z o.o. · Grudzadz, Poland
  • AES - DRS - Synexus Watermeyer Clinical Research Centre · Pretoria, South Africa
  • CHUS-Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  • PharmaSite · Malmö, Sweden
Show 11 removed
  • ClinSearch, LLC · Chattanooga, United States
  • Centro de Diagnostico Y Rehabilitacion · Santa Fe, Argentina
  • Centrum Medyczne CLW-med Aneta Cichomska , Joanna Luka -Wendrowska · Grudzadz, Poland
  • Centrum Alergologii Teresa Hofman · Poznan, Poland
  • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  • The First Hospital of Changsha · Changsha, China
  • The Third Hospital of Changsha · Changsha, China
  • AES - DRS - Synexus Berlin Research Centre · Berlin, Germany
  • Okayama Rosai Hospital · Okayama-Shi Minami-ku, Japan
  • AES - DRS - Synexus Watermeyer Clinical Research Centre · Pretoria, South Africa
  • PharmaSite · Malmö, Sweden
across 2 updates, Nov 12, 2026 – Nov 13, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedCompletion of the 52-week treatment period in eitheran astegolimab parent GB43311 or GB44332study
Nov 12, 2026
Contact
Study contact now listed: added g•••@gene.com · •••6728; added (no phone or email listed). See the current contact
Nov 12, 2026
Show all 2 updates
  1. Nov 13, 2026
    Recruiting→Active, not recruiting
    6 sites removed
    Show 6 removed
    • The First Hospital of Changsha · Changsha, China
    • The Third Hospital of Changsha · Changsha, China
    • AES - DRS - Synexus Berlin Research Centre · Berlin, Germany
    • Okayama Rosai Hospital · Okayama-Shi Minami-ku, Japan
    • AES - DRS - Synexus Watermeyer Clinical Research Centre · Pretoria, South Africa
    • PharmaSite · Malmö, Sweden
    + 1 other change: contact details
  2. Nov 12, 2026
    Active, not recruiting→Recruiting
    10 sites added, 5 sites removed. 476 sites changed recruiting status (444 now recruiting, 18 now completed, …)
    Show 476 sites
    • UAB Lung Health Center · Birmingham, United Statesno status→Recruiting
    • SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS · Dothan, United Statesno status→Recruiting
    • Jasper Summit Research LLC · Jasper, United Statesno status→Recruiting
    • Pulmonary Associates of Mobile PC · Mobile, United Statesno status→Recruiting
    • Pulmonary Associates Deer Valley Office · Phoenix, United Statesno status→Recruiting
    • AES - DRS - Synexus Clinical Research US, Inc. - Tucson · Tucson, United Statesno status→Recruiting
    • Kern Allergy and Medical Research · Bakersfield, United Statesno status→Recruiting
    • Cadena Care Institute, LLC · Poway, United Statesno status→Recruiting
    • Apex Clinical Research · San Diego, United Statesno status→Completed
    • St Francis Medical Institute ClinEdge PPDS · Clearwater, United Statesno status→Recruiting
    • Finlay Medical Research Corporation · Greenacres City, United Statesno status→Recruiting
    • Flourish Research - Leesburg - PPDS · Leesburg, United Statesno status→Recruiting
    • Advanced Pulmonary Research Institute · Loxahatchee Groves, United Statesno status→Recruiting
    • San Marcus Research Clinic Inc. · Miami, United Statesno status→Recruiting
    • Finlay Medical Research Corporation · Miami, United Statesno status→Recruiting
    • Oceane7 Medical & Research Center, Inc. · Miami, United Statesno status→Recruiting
    • Research Institute of South Florida Inc · Miami, United Statesno status→Recruiting
    • Diverse Clinical Research, LLC · Miami, United Statesno status→Recruiting
    • Central Florida Pulmonary Group, PA · Orlando, United Statesno status→Recruiting
    • Florida Institute for Clinical Research, LLC · Orlando, United Statesno status→Recruiting
    • Flourish Research - Orlando - PPDS · Winter Park, United Statesno status→Recruiting
    • Pivotal Research Solutions · Stonecrest, United Statesno status→Recruiting
    • Northwestern Center for Clinical Research · Chicago, United Statesno status→Recruiting
    • ASHA Clinical Research - ClinEdge - PPDS · Hammond, United Statesno status→Recruiting
    • Best Clinical Trials · New Orleans, United Statesno status→Recruiting
    • Paul A. Shapero, MD, PA · Bangor, United Statesno status→Recruiting
    • Exordia Medical Research, Inc. · Fall River, United Statesno status→Recruiting
    • Pulmonary Research Institute of Southeast Michigan · Farmington Hills, United Statesno status→Recruiting
    • Flushing Road Internal Medicine and Pediatrics - F · Flint, United Statesno status→Recruiting
    • Revive Research Institute · Southfield, United Statesno status→Recruiting
    • …and 446 more on the registry record
    Show 10 added (2 China, 2 Poland, 1 United States, 1 Argentina, 1 Germany, 1 South Africa, 1 Spain, 1 Sweden)
    • ClinSearch, LLC - M3 WR - 6035 Shallowford Rd · Chattanooga, United States
    • CEDIR - Centro de Diagnóstico Y Rehabilitación · Santa Fe, Argentina
    • The First Hospital of Changsha · Changsha, China
    • The Third Hospital of Changsha · Changsha, China
    • AES - DRS - Synexus Berlin Research Centre · Berlin, Germany
    • Centrum Alergologii sp. z.o.o. · Poznan, Poland
    • Centrum Medyczne Lukamed sp. z o.o. · Grudzadz, Poland
    • AES - DRS - Synexus Watermeyer Clinical Research Centre · Pretoria, South Africa
    • CHUS-Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
    • PharmaSite · Malmö, Sweden
    Show 5 removed
    • ClinSearch, LLC · Chattanooga, United States
    • Centro de Diagnostico Y Rehabilitacion · Santa Fe, Argentina
    • Centrum Medyczne CLW-med Aneta Cichomska , Joanna Luka -Wendrowska · Grudzadz, Poland
    • Centrum Alergologii Teresa Hofman · Poznan, Poland
    • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedCompletion of the 52-week treatment period in eitheran astegolimab parent GB43311 or GB44332study
    Contact Study contact now listed: added g•••@gene.com · •••6728; added (no phone or email listed). See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05878769
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jun 28, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion